Japanese clinical research and regulatory frameworks have evolved considerably in the past two decades to reduce the delay in the introduction of new drugs in Japan compared with other major markets. However, recently introduced changes related to access to unapproved drugs might have the opposite effect and might not benefit all patients.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fujiwara, Y. & Kobayashi, K. Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). Crit. Rev. Oncol. Hematol. 42, 145–155 (2002).
Kagayama, K. & Ono, S. Actual performance of Japanese clinical development and regulatory review (2000-2014). Research Paper Series No. 68 (November 2015), Office of Pharmaceutical Industry Research, The Japan Pharmaceutical Manufacturers Association (in Japanese) http://www.jpma.or.jp/opir/research/rs_068/article_068.html (2015)
Fujiwara, Y., Yonemori, K., Shibata, T., Okita, N. & Ushirozawa, N. Japanese universal health care faces a crisis in cancer treatment. Lancet Oncol. 16, 251–252 (2015).
The author would like to thank B. A. Chabner, F. Pignatti, C. Matsuda and H. Ozaki for their valuable insights during the development of this article.
Y.F. has received a grant and a contract from the Ministry of Health, Labour and Welfare (MHLW), Japan, and a grant from the Japan Agency for Medical Research and Development between April 2013 and March 2016. He served on several committees or as a research program officer of the MHLW, Japan, the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Japan Agency for Medical Research and Development. He has received lecture fees from AstraZeneca KK, Eisai Co. Ltd, Sanofi-Aventis KK, Daichi Sankyo Co. Ltd, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan KK, Yakult Honsha Co. Ltd and NEC corporation between April 2013 and March 2016. He has received research grants from Taiho Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, Takeda Bio Development Center Ltd, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan KK and Nippon Kayaku Co. Ltd between April 2013 and March 2016.
About this article
Cite this article
Fujiwara, Y. Evolution of frameworks for expediting access to new drugs in Japan. Nat Rev Drug Discov 15, 293–294 (2016). https://doi.org/10.1038/nrd.2016.68
Therapeutic Innovation & Regulatory Science (2022)
Comparative Assessment of Non-trial Access to Investigational Medical Products in the U.S. and Japan
Therapeutic Innovation & Regulatory Science (2021)